{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:19:54Z","timestamp":1791825594731,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaut.2024.103233","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T20:11:39Z","timestamp":1716667899000},"page":"103233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Cannabinoid receptor 2 selective agonist alleviates systemic sclerosis by inhibiting Th2 differentiation through JAK\/SOCS3 signaling"],"prefix":"10.1016","volume":"147","author":[{"given":"Na","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinnan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Ming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103233_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2024.103233_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib3","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1172\/JCI131700","article-title":"Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis","volume":"130","author":"Maehara","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103233_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/BOR.0000000000000644","article-title":"T and B lymphocytes in fibrosis and systemic sclerosis","volume":"31","author":"Pillai","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103233_bib5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2004.027094","article-title":"Early T cell activation in the skin from patients with systemic sclerosis","volume":"64","author":"Kalogerou","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the T(H)1\/T(H)2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103233_bib7","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2024.103233_bib8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1084\/jem.194.6.809","article-title":"Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)","volume":"194","author":"Lee","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103233_bib9","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","article-title":"Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via Gremlin protein","volume":"289","author":"O'Reilly","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2024.103233_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000163802","article-title":"In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease","volume":"61","author":"Koch","year":"1993","journal-title":"Pathobiology"},{"key":"10.1016\/j.jaut.2024.103233_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2024.103233_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nri1602","article-title":"Cannabinoid-based drugs as anti-inflammatory therapeutics","volume":"5","author":"Klein","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103233_bib13","doi-asserted-by":"crossref","first-page":"13320","DOI":"10.1074\/jbc.M707960200","article-title":"The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis","volume":"283","author":"Palazuelos","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2024.103233_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm1561","article-title":"Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells","volume":"13","author":"Maresz","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2024.103233_bib15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/ecco-jcc\/jjx096","article-title":"Cannabinoid receptor-2 ameliorates inflammation in murine model of Crohn's disease","volume":"11","author":"Leinwand","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaut.2024.103233_bib16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jaci.2021.09.037","article-title":"Cannabinoid receptor 2 engagement promotes group 2 innate lymphoid cell expansion and enhances airway hyperreactivity","volume":"149","author":"Hurrell","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103233_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/ket447","article-title":"Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis","volume":"53","author":"Gui","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2024.103233_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.01.008","article-title":"Activation and signaling mechanism revealed by cannabinoid receptor-G(i) complex structures","volume":"180","author":"Hua","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2024.103233_bib19","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.96.25.14228","article-title":"HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor","volume":"96","author":"Hanus","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2024.103233_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2024.103233_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9","article-title":"Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure","volume":"41","author":"Zurier","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103233_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bcp.2019.02.029","article-title":"Cannabinoid derivatives acting as dual PPARgamma\/CB2 agonists as therapeutic agents for systemic sclerosis","volume":"163","author":"Garcia-Martin","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jaut.2024.103233_bib23","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103233_bib24","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib25","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1523-1747.1999.00528.x","article-title":"Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma","volume":"112","author":"Yamamoto","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2024.103233_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple method of estimating severity of pulmonary fibrosis on a numerical scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jaut.2024.103233_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-016-0993-2","article-title":"Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma","volume":"18","author":"Fava","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2024.103233_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41584-020-0404-6","article-title":"T cells in SSc skin lesions: knowing your enemy","volume":"16","author":"Fuschiotti","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103233_bib29","first-page":"328","article-title":"Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis","volume":"24","author":"Hasegawa","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103233_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.autrev.2010.08.003","article-title":"Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis","volume":"10","author":"Baraut","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103233_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/mol.114.094649","article-title":"CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?","volume":"86","author":"Dhopeshwarkar","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jaut.2024.103233_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nri.2017.118","article-title":"T(H)2 cell development and function","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103233_bib33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nm896","article-title":"SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses","volume":"9","author":"Seki","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2024.103233_bib34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/annrheumdis-2021-220209","article-title":"Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis","volume":"80","author":"Gaydosik","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41584-023-01044-x","article-title":"Systemic sclerosis interstitial lung disease: unmet needs and potential solutions","volume":"20","author":"Liakouli","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103233_bib36","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib38","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/art.40016","article-title":"Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor beta and activate fibroblasts","volume":"69","author":"Dumoitier","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103233_bib39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.2008.104299","article-title":"Antifibroblast antibodies from systemic sclerosis patients bind to alpha-enolase and are associated with interstitial lung disease","volume":"69","author":"Terrier","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103233_bib41","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard-2023-224184","article-title":"Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups","volume":"82","author":"Clark","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866549","article-title":"T helper 2-associated immunity in the pathogenesis of systemic lupus erythematosus","volume":"13","author":"Ko","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103233_bib43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/ard.2010.137539","article-title":"The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model","volume":"70","author":"Balistreri","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104994","article-title":"Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis","volume":"143","author":"Navarrete","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jaut.2024.103233_bib45","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","article-title":"Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts","volume":"48","author":"Garcia-Gonzalez","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2024.103233_bib46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2020.01.007","article-title":"Cryo-EM structure of the human cannabinoid receptor CB2-G(i) signaling complex","volume":"180","author":"Xing","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2024.103233_bib47","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.1656","article-title":"Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression","volume":"9","author":"Liao","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2024.103233_bib48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-7613(03)00292-9","article-title":"Stat5 activation plays a critical role in Th2 differentiation","volume":"19","author":"Zhu","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2024.103233_bib49","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1084\/jem.20052333","article-title":"Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1","volume":"203","author":"Kinjyo","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103233_bib50","doi-asserted-by":"crossref","first-page":"8137","DOI":"10.1073\/pnas.0600666103","article-title":"Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2024.103233_bib51","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/cea.14385","article-title":"Aberrant expression of suppressor of cytokine signaling (SOCS) molecules contributes to the development of allergic diseases","volume":"53","author":"Jafarzadeh","year":"2023","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.jaut.2024.103233_bib52","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/ATVBAHA.110.207464","article-title":"Suppressors of cytokine signaling (SOCS) proteins and JAK\/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3","volume":"31","author":"Tamiya","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T20:30:32Z","timestamp":1720816232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124000672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":52,"alternative-id":["S0896841124000672"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103233","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid receptor 2 selective agonist alleviates systemic sclerosis by inhibiting Th2 differentiation through JAK\/SOCS3 signaling","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103233"}}